



## **Aerie Pharmaceuticals to Present at the Stifel 2019 Healthcare Conference**

November 12, 2019

DURHAM, N.C.--(BUSINESS WIRE)--Nov. 12, 2019-- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other diseases of the eye today announced that Vicente Anido, Jr., Ph.D., Chairman and Chief Executive Officer, will present in a fireside discussion at the Stifel 2019 Healthcare Conference on Tuesday, November 19, 2019 at 3:35 p.m. Eastern Time in New York, NY. Dr. Anido will provide an Aerie overview and provide a business update.

The fireside discussion will be webcast live and may be accessed by visiting Aerie's website at <http://investors.aeriepharma.com>. A replay of the webcast will be available for 10 business days.

### **About Aerie Pharmaceuticals, Inc.**

Aerie is an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other diseases of the eye. Aerie's first product, Rhopressa<sup>®</sup> (netarsudil ophthalmic solution) 0.02%, a once-daily eye drop approved by the U.S. Food and Drug Administration (FDA) for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension, was launched in the United States in April 2018. In clinical trials of Rhopressa<sup>®</sup>, the most common adverse reactions were conjunctival hyperemia, corneal verticillata, instillation site pain, and conjunctival hemorrhage. More information about Rhopressa<sup>®</sup>, including the product label, is available at [www.rhopressa.com](http://www.rhopressa.com). Aerie's second product for the reduction of elevated IOP in patients with open-angle glaucoma or ocular hypertension, Rocklatan<sup>®</sup> (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005%, the first and only fixed-dose combination of Rhopressa<sup>®</sup> and the widely-prescribed PGA (prostaglandin analog) latanoprost, has been approved by the FDA and was launched in the United States in the second quarter of 2019. In clinical trials of Rocklatan<sup>®</sup>, the most common adverse reactions were conjunctival hyperemia, corneal verticillata, instillation site pain, and conjunctival hemorrhage. More information about Rocklatan<sup>®</sup>, including the product label, is available at [www.rocklatan.com](http://www.rocklatan.com). Aerie continues to focus on global expansion and the development of additional product candidates and technologies in ophthalmology, including for wet age-related macular degeneration and diabetic macular edema. More information is available at [www.aeriepharma.com](http://www.aeriepharma.com).

View source version on businesswire.com: <https://www.businesswire.com/news/home/20191112005038/en/>

Source: Aerie Pharmaceuticals, Inc.

Aerie Pharmaceuticals, Inc.

Media: Tad Heitmann 949-526-8747; [theitmann@aeriepharma.com](mailto:theitmann@aeriepharma.com)

Investors: Ami Bavishi 908-947-3949; [abavishi@aeriepharma.com](mailto:abavishi@aeriepharma.com)